BIO (Bio-Rad Laboratories) Cash-to-Debt : 1.36 (As of Sep. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bio-Rad Laboratories's cash to debt ratio for the quarter that ended in Sep. 2024 was 1.36.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bio-Rad Laboratories could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Bio-Rad Laboratories's Cash-to-Debt or its related term are showing as below:

BIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.14 Med: 1.64 Max: 5.94
Current: 1.16

During the past 13 years, Bio-Rad Laboratories's highest Cash to Debt Ratio was 5.94. The lowest was 1.14. And the median was 1.64.

BIO's Cash-to-Debt is ranked worse than
58.09% of 859 companies
in the Medical Devices & Instruments industry
Industry Median: 1.83 vs BIO: 1.16

Bio-Rad Laboratories Cash-to-Debt Historical Data

The historical data trend for Bio-Rad Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bio-Rad Laboratories Cash-to-Debt Chart

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.71

4.39

3.89

1.29

1.14

Bio-Rad Laboratories Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															1.25	1.14	1.38	1.35	1.36

Competitive Comparison of Bio-Rad Laboratories's Cash-to-Debt

For the Medical Devices subindustry, Bio-Rad Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cash-to-Debt falls into.

Bio-Rad Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bio-Rad Laboratories's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1607.142	/	(40.865	+	1364.578)
	=	1.14

Bio-Rad Laboratories's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1628.018	/	(1.262	+	1200.062)
	=	1.36

Bio-Rad Laboratories (NYSE:BIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bio-Rad Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIO.B:USA BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Executives

Tania Devilliers	officer: INT PRIN ACCTG OFC	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen	officer: EVP, Global Human Resources	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May	officer: EVP, President, LSG	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last	officer: EVP, Chief Operating Officer	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam	officer: SVP, Chief Accounting Officer	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal	officer: EVP, Chief Financial Officer	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst	officer: EVP, General Counsel & Sec	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright	officer: Executive Vice President	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley	officer: EVP, GBL Commercial Operations	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz	10 percent owner	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz	director, 10 percent owner
Norman D Schwartz	director, 10 percent owner, officer: Chairman, President, and CEO	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547